Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
TEL AVIV - Nasus Pharma Ltd. (NYSE:NSRX), a clinical-stage pharmaceutical company developing intranasal products for emergency medical conditions, has completed its initial public offering, raising $10 million in gross proceeds.
The company sold 1,250,000 ordinary shares at $8.00 per share, according to a press release statement issued Thursday. Nasus Pharma’s shares began trading on the NYSE American LLC exchange on Wednesday under the ticker symbol NSRX.
The underwriters, Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC, have been granted an option to purchase up to an additional 187,500 ordinary shares within 45 days from the final prospectus date.
Nasus Pharma plans to use the net proceeds to advance its intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies. Remaining funds will support general corporate purposes, working capital, and capital expenditures.
The company’s lead product candidate, NS002, is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. The technology uses powder-based intranasal formulation designed for rapid drug delivery through the nasal cavity’s vascular network.
The registration statement for the offering was declared effective by the Securities and Exchange Commission on August 12, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.